Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants
Launched by MEDICAL UNIVERSITY OF VIENNA · Feb 26, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help extremely preterm infants breathe better while they are on a specific type of ventilation called High Frequency Oscillatory Ventilation (HFOV). The researchers want to see if a method that involves adjusting the lung settings based on oxygen levels can improve how well these infants are getting oxygen. The goal is to lower a measurement called the oxygen saturation index (OSI), which helps doctors understand how effectively the lungs are working.
To be eligible for this study, infants must be born before 28 weeks of pregnancy and not older than 29 weeks of postmenstrual age. They should be receiving HFOV for their breathing support. However, infants with certain heart, lung, or brain problems, or those with specific genetic conditions, cannot participate. If eligible, parents can expect their infants to be closely monitored during the trial, and their healthcare team will provide information and support throughout the process.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Preterm infants
- • born below 28 weeks of gestational age
- • not older than 29 weeks of postmenstrual age
- • receive HFOV
- Exclusion Criteria:
- • known congenital anomalies of the heart, of the lung, and/or of the central nervous system
- • known chromosomal abnormalities
- • participation in other intervention trials
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Tobias Werther
Principal Investigator
Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials